Saltar al contenido
Merck

SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients.

bioRxiv : the preprint server for biology (2020-09-17)
Juan A Pérez-Bermejo, Serah Kang, Sarah J Rockwood, Camille R Simoneau, David A Joy, Gokul N Ramadoss, Ana C Silva, Will R Flanigan, Huihui Li, Ken Nakamura, Jeffrey D Whitman, Melanie Ott, Bruce R Conklin, Todd C McDevitt
RESUMEN

Although COVID-19 causes cardiac dysfunction in up to 25% of patients, its pathogenesis remains unclear. Exposure of human iPSC-derived heart cells to SARS-CoV-2 revealed productive infection and robust transcriptomic and morphological signatures of damage, particularly in cardiomyocytes. Transcriptomic disruption of structural proteins corroborated adverse morphologic features, which included a distinct pattern of myofibrillar fragmentation and numerous iPSC-cardiomyocytes lacking nuclear DNA. Human autopsy specimens from COVID-19 patients displayed similar sarcomeric disruption, as well as cardiomyocytes without DNA staining. These striking cytopathic features provide new insights into SARS-CoV-2 induced cardiac damage, offer a platform for discovery of potential therapeutics, and raise serious concerns about the long-term consequences of COVID-19.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
FIBRONECTINA DEL PLASMA HUMANO, liquid, 0.1% (Solution), BioReagent, suitable for cell culture
Sigma-Aldrich
Seroalbúmina bovina, cold ethanol fraction, pH 5.2, ≥96%
Sigma-Aldrich
Proteína interferón-β recombinante humana, Recombinant Human Interferon Beta 1a (Hu-IFNbeta 1a).